Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million.
Founded in 2016, Laekna, Inc. is a science-driven, clinical-stage biotechnology company. It has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials and has initiated one clinical trial and another five clinical trials for its core products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers.
The Davis Polk corporate team included partners Xuelin (Steve) Wang, Yang Chu and Jason Xu, associates Jenny Ho and Michelle Chow and registered foreign lawyers Wentian Xie and Haiyang Zhao. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.
Related Posts
Antalpha Ventures, Web3Labs, and Goldford-HB Launch Computational Power Fund for AI and Web3 Projects
Antalpha Ventures, a global investment firm at the forefront of cutting-edge technology, has partnered with renowned Asian Web3 incubator Web3Labs and venture capital firm Goldford-HB to launch a new computational power fund. This fund aims to support early to mid-stage AI and Web3 projects worldwide by providing the necessary computational resources. Fund Back
MDHC Technologies Secures Series B Funding to Accelerate Growth and Innovation (2024)
MDHC Technologies completed a Series B funding round with investors including Chery Automobile, LAKSIMI Capital, Lucion Venture Capital Group, Yongxin Fangzhou, Addor Capital, and others. The funding will accelerate the development of its intelligent manufacturing platform, expand production capacity, and increase R&D investment, driving innovation and mark
Pillar Biosciences Partners with AstraZeneca to Accelerate Access to Liquid Biopsy Testing (September, 2024)
In September 2024, Pillar Biosciences announced a strategic partnership with AstraZeneca to expand laboratory access to molecular testing in Europe and the UK using rapid, affordable NGS-based liquid biopsy tumor profiling kits. The collaboration leverages Pillar’s oncoReveal™ liquid biopsy panels to deliver highly sensitive and specific tumor genetic varia
Unveiled the “Shushan” cryogenic CMOS quantum control chipset (March, 2025)
Unveiled the “Shushan” cryogenic CMOS quantum control chipset, including “Gongga” (superconducting qubit control), “Emei” (qubit readout), and “Xiling” (silicon-based qubit control) chips. “Xiling” was presented at ISSCC 2025, reducing system noise and power consumption for large-scale qubit arrays. Ne